Determination of the minimum fully protective dose of adenovirus-based DIVA vaccine against peste des petits ruminants virus challenge in East African goats by unknown
Holzer et al. Vet Res  (2016) 47:20 
DOI 10.1186/s13567-016-0306-4
RESEARCH ARTICLE
Determination of the minimum fully 
protective dose of adenovirus-based DIVA 
vaccine against peste des petits ruminants virus 
challenge in East African goats
Barbara Holzer1, Geraldine Taylor1, Paulina Rajko‑Nenow1, Sophia Hodgson1, Edward Okoth2, 
Rebecca Herbert1, Philip Toye2 and Michael D. Baron1*
Abstract 
Peste des petits ruminants virus (PPRV) causes an economically important disease of sheep and goats, primarily in 
developing countries. It is becoming the object of intensive international control efforts. Current vaccines do not 
allow vaccinated and infected animals to be distinguished (no DIVA capability). We have previously shown that 
recombinant, replication‑defective, adenovirus expressing the PPRV H glycoprotein (AdH) gives full protection against 
wild type PPRV challenge. We have now tested lower doses of the vaccine, as well as AdH in combination with a simi‑
lar construct expressing the PPRV F glycoprotein (AdF). We show here that, in a local breed of goat in a country where 
PPR disease is common (Kenya), as little as 107 pfu of AdH gives significant protection against PPRV challenge, while a 
vaccine consisting of 108 pfu of each of AdH and AdF gives apparently sterile protection. These findings underline the 
utility of these constructs as DIVA vaccines for use in PPR control.
© 2016 Holzer et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Peste des petits ruminants (PPR) is an important disease 
of sheep and goats which has recently become a major 
international target for improved control, marked by the 
adoption in 2014 of a resolution by the World Organi-
sation for Animal Health (OIE) to establish a control 
programme with a view to eventual eradication of the 
disease [1]. The disease is caused by a morbillivirus, PPR 
virus (PPRV), closely related to the human pathogen 
measles virus (MV), as well as other animal pathogens 
such as canine distemper virus (CDV) and rinderpest 
virus (RPV). PPRV is widely distributed through large 
parts of Africa, the Middle East and Asia and is responsi-
ble for significant economic losses, primarily in develop-
ing countries [2–5].
Disease control is mostly achieved through the use 
of clinical or laboratory-based diagnosis coupled with 
vaccination. All the vaccines currently in use are atten-
uated strains of PPRV [6, 7]; these vaccines are effec-
tive, though they do not provide a DIVA (distinguishing 
infected from vaccinated animals) capability. These vac-
cines cause what is essentially a subclinical infection 
with PPRV, and therefore the antibody signatures of vac-
cinated and previously-infected animals are identical. 
Several alternative DIVA vaccines have been proposed 
based on recombinant viruses [8–13]. We have shown 
that recombinant replication-defective human adenovi-
rus type 5 (Ad5) expressing the H surface glycoprotein of 
PPRV can act as a DIVA vaccine, inducing good levels of 
antibodies and protecting goats from experimental chal-
lenge with a pathogenic PPRV 4 months post vaccination 
[9]. Similar constructs have also been shown to be immu-
nogenic in other studies [10, 11] or, more recently, both 
immunogenic and protective in sheep [8]. We have car-
ried out an extended study of such recombinant adenovi-
rus constructs in goats in East Africa, an area where PPR 
is endemic. Using local animals, we have analysed the 
immunogenicity and protective efficacy of different doses 
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of vaccine, in order to determine the minimum protec-
tive dose. We have also compared the protection induced 
by Ad5-H alone to that induced by a vaccine combin-
ing Ad5-H with a similar construct expressing the other 
PPRV surface glycoprotein, F.
Materials and methods
Cells and viruses
Vero cells expressing the canine version of the morbilli-
virus receptor SLAM (signalling lymphocyte activation 
molecule) (vero-dog-SLAM, VDS) were obtained from 
Dr Paul Duprex, then at Queen’s University Belfast, N. 
Ireland, and maintained in Dulbecco’s modified Eagle’s 
medium containing 25  mM HEPES buffer, penicillin 
(100  U/mL), and streptomycin (100  µg/mL) (DMEM) 
containing 10% foetal calf serum (FCS). Zeocin was 
included at 0.1  mg/mL to maintain selection for SLAM 
expression. PPRV Ivory Coast/89 isolate [14] and recom-
binant PPRV rPPRV-GFP [15] were propagated and 
titrated in VDS cells. Titres were determined as the 50% 
tissue culture infectious dose (TCID50), calculated by 
the method of Spearman and Kärber [16]. Recombinant 
adenoviruses expressing ovine IL-2 (AdIL-2), PPRV H 
(AdH) or PPRV F (AdF), as well as the control adenovirus 
construct expressing GFP (AdGFP) were those previously 
described [9].
Animal study
The animal study was approved by the Institutional Ani-
mal Care and Use Committee (IACUC) and Institutional 
Biosafety Committee (IBC) at the International Live-
stock Research Institute, Nairobi (ILRI) and the National 
Biosafety Authority (NBA) in Kenya. Forty-eight locally 
acquired goats (Small East African Goat breed) were 
housed in a containment barn that was proofed against 
insect and tick vectors. All the animals were tested imme-
diately prior to vaccination for the presence of anti-PPRV 
antibodies using the PPRV H protein-specific cELISA, 
and found to be negative. The animals were divided into 
eight groups of six animals, which were vaccinated as 
described in Table 1. Blood samples for the preparation 
of serum were taken before vaccination and at 2, 3, 4 and 
12  weeks post vaccination. At 12  weeks post vaccina-
tion, all remaining animals (n = 42) were challenged with 
2 × 105 TCID50 of PPRV Ivory Coast/89 [9, 14] delivered 
intranasally. Rectal temperatures were recorded daily, 
and the animals monitored daily for clinical signs, for 
14 days after challenge. Blood was taken in EDTA on days 
0, 2, 4, 6, 8, 10, 12 and 14 days post challenge and stored 
at −70  °C until tested for the presence of PPRV RNA. 
Samples of blood were taken at 7 and 14 days post infec-
tion to prepare serum.
Other assays
Assays for serum antibodies specific for the PPRV H 
glycoprotein and the PPRV nucleocapsid (N) protein, 
for PPRV neutralising antibodies were as previously 
described [9] Viral RNA was assayed in 6% of the RNA 
extracted from 100 μL EDTA blood, using reverse tran-
scription-real time PCR as described [17].
Statistical analyses
Comparisons between groups were performed using lin-
ear mixed models in which animals were taken to be ran-
dom factors and the other factors as fixed; calculations 
were performed using the nlme package in R. Multiple 
comparisons were carried out by using the Tukey cor-
rected 95% confidence intervals as implemented in the R 
package multcomp, and quoted probability (p) values are 
from that package.
Results
Previous studies demonstrated that a single dose of 109 pfu 
of AdH induced complete protection against PPRV, when 
goats were challenged 4 months after vaccination. There-
fore, the present animal study was designed to determine if 
(i) the AdH vaccine is still protective at 108 or 107 pfu per 
animal; (ii) it delivers improved protection when combined 
with AdF (as suggested by [10]); (iii) there is an adjuvant 
effect of co-expressing IL-2, as suggested by some data 
from our previous study [9]. Seven groups, of six animals 
each, were vaccinated with different amounts and com-
binations of replication-defective adenovirus constructs 
as described in “Materials and methods” section, with an 
eighth group kept as control animals. Six animals of the 
total 48, from different groups, died of an unspecified res-
piratory infection between vaccination and challenge, so 
only partial serology data is available for those animals.
All the vaccinated animals developed a strong anti-
body response to the PPRV surface glycoprotein H, as 
Table 1 Amounts of each recombinant adenovirus given 
to each animal in the experimental groups
Viruses were diluted in PBS and delivered intramuscularly in a volume of 1 mL 
per animal.
Group number Vaccine
1 107 AdH + 107 AdGFP
2 108 AdH + 108 AdGFP
3 107 AdH + 107 AdIL‑2
4 108 AdH + 108 AdIL‑2
5 107 AdH + 107 AdF
6 108 AdH + 108 AdF
7 107 AdH + 107 AdF + 107 AdIL‑2
8 108 AdGFP + 108 AdIL‑2
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measured by competition ELISA [18] (Figure  1A). This 
was true even of those animals given the lowest dose 
of vaccine (107 pfu per animal). Groups 5 (107 pfu each 
of AdF and AdH) and 7 (107 pfu each of AdF, AdH and 
AdIL-2) showed significantly lower H antibody response 
to vaccination as measured in the cELISA, although still 
strongly positive (>70% inhibition). Group 5 showed a 
lower response than all groups except group 7 (p < 0.001 
for comparison with groups 1, 2, 3, 4 and 6), while group 
7 showed a lower response than groups 1, 2, 4 and 6 
(p = 0.003 for comparison with group 1 and p < 0.001 for 
the rest). In the absence of AdF, there was no significant 
difference between the anti-H antibody response in ani-
mals given 107 or 108 pfu AdH (group 1 vs group 2, and 
group 3 vs group 4). The addition of AdIL-2 had no effect 
on induction of anti-H antibody (comparing groups 1 
and 3 or groups 2 and 4), although it did improve the 
antibody response to low dose AdH  +  AdF (compari-
son of groups 5 and 7). As expected, antibodies to PPRV 
H protein were not detected in the negative control 
animals until the normal response to the challenge virus 
at 14 days post infection (dpi) (Figure 1A).
PPRV-specific serum neutralising antibodies were also 
analysed (Figure 1B). The two assays gave broadly com-
parable results, although the cELISA was more sensitive. 
Again, group 5 showed lower antibody responses dur-
ing the period prior to challenge than the other groups, 
although this time there was no statistically significant 
difference between groups 5 and 3. Group 7 animals 
showed a significantly higher neutralising antibody 
response than group 5 (p = 0.034), but were not signifi-
cantly different to any of the other groups. Group 3 was 
significantly lower than groups 4 and 6. Notably, inclu-
sion of AdF in the vaccination inoculum either reduced 
the neutralising antibody response (group 1 vs group 5) 
or made no difference (group 2 vs group 6; group 3 vs 
group 7).
All animals were challenged with 104 TCID50 of wild 
type PPRV Ivory Coast/89 at 12 weeks after vaccination. 
This isolate caused severe disease in UK goats [14]. How-
ever, in the local breed of goats available in Nairobi, the 
clinical response was almost undetectable, with mini-
mal temperature changes and no sustained clinical signs. 
In order to resolve the extent of protection provided by 
the vaccine, we therefore considered the presence or 
absence of PPRV RNA in blood samples during the chal-
lenge (taken as a measure of viraemia) and the immune 
response to other PPRV proteins, an extremely sensitive 
measure of virus replication, even in the absence of clini-
cal signs of disease. All five unvaccinated control animals 
developed clear viraemia (Figure 2A). In contrast, none of 
the vaccinated animals showed any detectable viraemia, 
apart from one animal in group 5, on 1 day (Figure 2B). 
All other samples were negative.
The development of antibodies to the PPRV N protein 
was determined using the N protein-specific competi-
tion ELISA (Figure 3). As expected, all the unvaccinated 
control animals developed a strong anti-N response by 
14  dpi. In addition, varying numbers of animals in the 
other experimental groups seroconverted to the PPRV 
N protein, showing at least some replication of the virus 
(Table  2). Most of the animals in groups 1 and 3 (107 
AdH) were N antibody positive. The only groups in which 
no animals were observed to seroconvert in response to 
N protein were group 6 (108 of both AdH and AdF) and 
group 7 (107 of each of AdH, AdF and AdIL-2).
Discussion
Comparison of the immunogenicity and protective effi-
cacy of different doses of Ad-expressed PPRV vaccines 
demonstrated that the recombinant adenovirus express-
ing the PPRV H, previously shown to be protective at a 
dose of 109 pfu per animal [9], is also protective at 108 pfu 
Figure 1 Antibody responses to recombinant adenovirus vac-
cine. The serum antibody response was determined after vaccination 
(blue bars) and after challenge (pink bars) as A the percent inhibition 
in the anti‑H cELISA and B the PPRV neutralisation titre. Error bars are 
one standard error of the mean (SEM).
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per animal (no detectable viraemia, limited replication of 
challenge virus). At 109 pfu per animal, in addition to pro-
tection from clinical PPRV, we also found complete sup-
pression of viraemia, although all the animals developed 
anti-N antibodies, showing that this test is an extremely 
sensitive test for replication of the challenge virus. At the 
lowest dose of AdH (107 pfu per animal), there was still a 
strong antibody response, and no viraemia, but more (3 
out of 5) of the animals developed anti-N antibodies.
Our data support the suggestion that the combina-
tion of AdH and AdF may be more protective than AdH 
alone, since group 6 restricted the challenge virus better 
than group 2, although the differences were marginal. 
However, we did not observe the increased PPRV-
neutralising titre seen by Wang et  al. [10] in goats vac-
cinated with an adenovirus expressing PPRV H and F. A 
significant difference between these two studies is that, 
in the present case, we expressed each protein sepa-
rately, so each had the possibility to fold into its native 
conformation. In the study by Wang et al. [10], F and H 
were expressed as a single fusion protein. Under these 
circumstances, neither protein is likely to fold normally. 
It has been shown that such misfolded proteins can be 
bound directly by MHC class II [19]; in addition, such a 
protein will be removed from the ER by the normal qual-
ity control system (reviewed in [20]) and degraded by the 
ER-associated protein degradation system, rapidly gen-
erating F/H protein-derived peptides which can be pre-
sented by both class I and class II systems [21, 22]. Such 
processes may have led to the higher levels of anti-PPRV 
antibody observed in response to their (F  +  H) fusion 
protein compared to AdF or AdH alone.
While it may not have played a role in their reported 
increased antibody response to Ad(F + H) compared to 
AdH, Wang et al. also vaccinated goats with two doses of 
adenovirus-vectored vaccine, whereas we have consid-
ered it desirable to have a vaccine that functions after a 
single dose, since this will be more practical in develop-
ing countries where the major cost and effort is in deliv-
ering vaccine to the animals.
The overall conclusion was therefore that the vaccine 
consisting of 108 (AdH + AdF) appears to be completely 
effective and provides a DIVA vaccine capability when 
used in conjunction with the existing commercial cELI-
SAs, which recognise antibodies to PPRV H or PPRV N. 
The protection was complete at 3 months post vaccina-
tion and with only a single dose of vaccine. However, a 
longer term study (at least 1 year) would be advisable to 
establish the duration of protection and the duration of 
detectable marker antibody (anti-H antibody).
A very interesting observation was that there appears 
to be a significant difference in the pathogenicity of 
the PPRV isolate in UK and E. African goats. Although 
this isolate (Ivory Coast/89) has been clearly virulent 
in studies at TPI, the same virus had little effect on the 
native breed of goats used at ILRI; transient high tem-
peratures were seen in several of the control animals, 
and none in the vaccinated animals (not shown), but 
this was not consistent across the group. Mild clinical 
signs were sometimes observed in different animals, but 
it was clear that the animals were not being kept iso-
lated from other infectious agents, as six animals died 
during the time between vaccination and challenge, 
and the significance of slight nasal discharge for 1 day is 
limited. The reasons for the lack of severe clinical signs 
of disease in the control animals, despite clear virus 
replication, and prolonged viraemia in most cases, are 
not clear. One possibility is that there is significant and 
general resistance to PPRV in the breed of goat used 
or, alternatively, resistance may be due to an interac-
tion of virus and host strain, so that viruses may appear 
pathogenic or mild depending on what hosts they have 
recently been in (the challenge strain had been passaged 
Figure 2 PPRV viraemia after challenge. Blood was collected 
from all animals at 2, 4, 6, 8, 10 and 12 dpi and stored at −70 °C until 
assay. Real‑time PCR was used to measure PPRV RNA, which is plot‑
ted as 45‑Ct, where Ct is the threshold cycle. A data from negative 
control animals; B data from group 5 animals. All other samples were 
completely negative for PPRV RNA.
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in UK goats). This has implications for surveillance for 
disease, as virus may be mild or inapparent when first 
entering a new country or an area with a different breed 
of goats or sheep.
Studies are necessary in local breeds of goats using 
local isolates of PPRV as well as other known pathogenic 
isolates. If some animals are able to support virus growth, 
and possibly spread, without showing significant clinical 
signs, this would make control measures based on clini-
cal surveillance alone insufficient.
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Figure 3 Development of antibodies to PPRV N protein. Serum samples before (A) and 14 days after (B) challenge were assayed for anti‑N 
antibodies using the N protein specific cELISA. In this assay, the read‑out is in percent of the monoclonal that remains bound (PB), so it has been 
plotted as 120‑PB so that the plotted value increases as the amount of anti‑N antibody increases. Values of (120‑PB) >70 (values of PB <50) are 
considered positive (dashed line).
Table 2 Development of antibodies to other PPRV pro-
teins
Numbers of animals in each group that were positive ((120-PB) >70%) for 
antibodies against PPRV N protein.
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